Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QA48 | ISIN: US00507W2061 | Ticker-Symbol: 7AY1
Tradegate
27.06.25 | 18:21
1,377 Euro
+10,78 % +0,134
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTINIUM PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACTINIUM PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2281,25819:03
1,2121,25727.06.

Aktuelle News zur ACTINIUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiH.C. Wainwright reiterates buy rating on Actinium Pharma stock6
09.05.Actinium Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
09.05.Actinium Pharmaceuticals, Inc. - 8-K, Current Report2
06.05.Actinium Pharmaceuticals, Inc.: Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center75- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with...
► Artikel lesen
31.03.Actinium Pharmaceuticals, Inc. - 10-K, Annual Report2
ACTINIUM Aktie jetzt für 0€ handeln
27.03.Actinium Pharmaceuticals unveils novel prostate cancer therapy7
25.03.EQS-News: Eckert & Ziegler SE: Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm602EQS-News: Eckert & Ziegler SE / Schlagwort(e): Vereinbarung/Auftragseingänge Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm...
► Artikel lesen
20.03.Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy142NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted...
► Artikel lesen
18.03.Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA and OPDIVO98- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes - MDSCs...
► Artikel lesen
17.03.Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia166- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy - ...
► Artikel lesen
17.03.Actinium Pharma Reports Publication Of Actimab-A + CLAG-M Results330WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with...
► Artikel lesen
18.11.24Actinium Pharma Q3 Loss Narrows392WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a...
► Artikel lesen
20.09.24Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology233Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approaches SIERRA...
► Artikel lesen
05.08.24Why Is Actinium Pharmaceuticals Stock Falling In Pre-market?519WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals (ATNM) issued a regulatory update on the planned Biologics License Application filing for Iomab-B in patients with active relapsed or refractory...
► Artikel lesen
05.08.24Actinium Pharmaceuticals, Inc.: Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.396FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint Additional head-to-head randomized clinical...
► Artikel lesen
25.07.24Actinium Pharmaceuticals, Inc.: Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University243- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need - Current conditioning with non-targeted...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2